Kalbe Farma Tbk PT

Kalbe Farma Tbk PT maintains a strong liquidity position, with a current ratio of 3.47 and a liquidity_fpt of 1.12, indicating that the company has more than enough current assets to cover its short-term liabilities. The company's cash and equivalents amount to 1.8 trillion IDR, and its operating cash flow of 3.27 trillion IDR supports its ability to fund operations and invest in growth. The company's profitability is robust, with a return on equity (ROE) of 15.72% and a return on assets (ROA) of 11.94%. These figures are well above the industry median for ROE and ROA, which are typically in the 8-10% range for pharmaceutical firms. Kalbe Farma's operating margin of 13.0% and net margin of 10.4% also reflect strong cost control and pricing power. Kalbe Farma's revenue is primarily concentrated in Indonesia, where it operates through multiple business segments, including OTC, prescription drugs, and consumer health. The company's largest segment, OTC, accounts for approximately 45% of total revenue, followed by prescription drugs at 35%. The company has a limited presence in international markets, with less than 5% of revenue derived from outside Indonesia. The company's growth trajectory is positive, with revenue expected to increase by 6.5% in the current fiscal year and 4.2% in the following year. This growth is driven by expansion in the OTC and consumer health segments, as well as the introduction of new products in the prescription drug category. The company's capital expenditure of -809.87 billion IDR indicates a focus on optimizing existing assets rather than large-scale new investments. Kalbe Farma's risk profile is relatively low, with a debt-to-equity ratio of 0.01 and no immediate filing-based liquidity or dilution flags. The company's low leverage and strong cash position reduce financial risk. Additionally, the company has not issued any new shares in the past year, and there are no indications of near-term dilution pressure. Recent events include the company's continued focus on innovation and product development, as well as its efforts to expand its market share in the domestic healthcare sector. Kalbe Farma has also been active in responding to regulatory changes in the pharmaceutical industry, ensuring compliance and maintaining its competitive position.